Novatim Immune Therapeutics (Zhejiang) Co., Ltd, a China-based specialist in cancer immunotherapy, has received tacit clinical trial approval from Chinese regulatory authorities for its investigational therapy, KQ-2003. This autologous chimeric antigen receptor (CAR)-T cell therapy targets BCMA and CD19 and is poised to be evaluated for the treatment of recurrent/refractory POEMS syndrome.
POEMS syndrome, a rare and complex multisystem disorder linked to plasma cell dysregulation, is characterized by polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes. The etiology of POEMS syndrome remains obscure, with neuropathies often presenting as the initial symptom. Elevated levels of vascular endothelial growth factor (VEGF) in serum are regarded as a key pathogenic mechanism in POEMS syndrome.
Beyond POEMS syndrome, KQ-2003 also holds potential as a treatment for recurrent/refractory multiple myeloma, showcasing the broad applicability of this innovative immunotherapeutic approach.- Flcube.com
